Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Combining nimotuzumab to gefitinib may not only potentiate cellular cytotoxicity, but may
also assist in overcoming inherent or acquired resistance to gefitinib alone.